Table of Contents

Research around weight loss drugs has exploded in recent years, particularly with GLP-1 receptor agonists such as semaglutide and tirzepatide. However, most GLP-1 drugs on the market are injectable peptides. Orforglipron aims to change that by offering a non-peptide, small-molecule pill taken once a day without food or water restrictions.

Orforglipron is an investigational once-daily oral GLP-1 pill for obesity and type 2 diabetes. In phase 3 trials, it produced up to 12.4% weight loss and up to 2.1% A1C reduction. It offers needle-free dosing, mostly gastrointestinal side effects, and potential FDA approval in 2026.

In this guide, we explain how orforglipron works, summarize the latest clinical trial data, and compare it to existing treatments. If you are considering a weight loss medication, the information below can help you have an informed conversation with your healthcare provider.

Key Takeaways

  • In the phase 3 ATTAIN 1 trial, Orforglipron 36 mg led to an average 12.4% body weight reduction at 72 weeks, compared with 0.9% on placebo.
  • In ACHIEVE trials involving adults with type 2 diabetes, Orforglipron reduced A1C by as much as 2.1%, outperforming placebo and showing stronger reductions than dapagliflozin in one study.
  • Unlike oral semaglutide, Orforglipron can be taken without strict timing, food, or water restrictions.
  • In ATTAIN-MAINTAIN, participants switching to Orforglipron regained only about 0.9 kg (2 lbs) from Wegovy versus 9 kg (19.8 lbs) or more on placebo.
  • The most common side effects of orforglipron were nausea, vomiting, diarrhea, and constipation, with discontinuation rates between 5.1% and 10.3% depending on dose.
  • Lilly submitted Orforglipron for obesity treatment in late 2025, with a US regulatory decision anticipated in spring 2026.
  • Self-pay retail pricing through the LillyDirect pharmacy channel is projected to start at $149 for the lowest dose and go up to $399 for higher doses. Final commercial list price and insurance coverage details are not yet disclosed.

How does orforglipron work?

Orforglipron is designed to activate the GLP-1 receptor on pancreatic and brain cells. By doing so, it increases insulin secretion, lowers glucagon levels, slows gastric emptying, and promotes satiety.

Activation of GLP-1 receptors leads to multiple metabolic benefits. In addition to stimulating insulin release, GLP-1 agonists slow down how quickly the stomach empties and send signals to the brain that reduce hunger. That combination decreases calorie intake and helps patients feel satisfied with smaller meals.

Orforglipron also lowers blood sugar (A1C) levels and may reduce cardiovascular risk markers such as non-HDL cholesterol, triglycerides, and systolic blood pressure.

Unlike oral semaglutide, Wegovy tablets and Rybelsus, which are peptides degraded by stomach enzymes, orforglipron is a small-molecule compound that can survive the digestive tract.

That means patients can take it with or without meals and do not need fasting conditions, as required for oral semaglutide. A once-daily pill could improve adherence compared with weekly injections or pills requiring strict schedules.

How effective is orforglipron?

How much weight can you lose on orforglipron

Orforglipron is being evaluated across the ATTAIN and ACHIEVE trial programs. The ATTAIN studies involve adults with obesity or overweight, while ACHIEVE trials focus on type 2 diabetes.

Trials compare different doses of orforglipron with placebo or other drugs. Results have been encouraging but vary by dose and patient population.

Weight loss efficacy in the ATTAIN program

The phase 3 ATTAIN 1 trial included more than 3,100 adults with obesity but without diabetes. Participants were randomly assigned to orforglipron 6 mg, 12 mg, or 36 mg once daily or placebo.

After 72 weeks, the highest 36 mg dose resulted in an average 12.4% body weight reduction (about 27.3 lbs) using the efficacy estimand. Lower doses produced 7.8% and 9.3% reductions, while the placebo only achieved 0.9%.

About 59.6% of participants receiving 36 mg lost at least 10% of their body weight, and 39.6% lost at least 15%.

The ATTAIN 2 trial examined adults with obesity or overweight who also had type 2 diabetes. Mean weight loss percentages at 72 weeks were slightly lower than those at ATTAIN 1, reflecting the metabolic challenge of diabetes.

Orforglipron 6 mg, 12 mg, and 36 mg doses produced average body weight reductions of 5.1%, 7.0%, and 9.6%, respectively, versus 2.5% with placebo. In this trial, 45.6% of participants on the highest dose achieved at least 10% weight loss compared with 9% on placebo. The trial also reported improvements in waist circumference, blood pressure, and lipid levels.

Weight maintenance after injectable treatments

For individuals who previously used injectable therapies, the ATTAIN-MAINTAIN trial investigated whether switching to orforglipron could sustain weight loss.

Participants first completed 72 weeks of semaglutide (Wegovy) or tirzepatide (Zepbound). At the 52-week follow-up, those switching to orforglipron maintained nearly all of the weight they had lost, with an average regain of only 0.9 kg (~2 lbs) when coming from Wegovy and about 5 kg (~11 lbs) after Zepbound.

In contrast, placebo participants regained 9 kg (~19.8 lbs) or more. These findings suggest that an oral GLP-1 pill could help sustain weight loss achieved with injections while avoiding needles.

Glycemic control in people with type 2 diabetes

The ACHIEVE program evaluates orforglipron’s impact on blood sugar. ACHIEVE 2 compared orforglipron to the SGLT 2 inhibitor dapagliflozin in adults with type 2 diabetes inadequately controlled on metformin.

Orforglipron lowered A1C by up to 1.7 percentage points compared to 0.8 points with dapagliflozin. Weight loss accompanied these improvements, and cardiovascular risk markers also improved.

In ACHIEVE 5, adults on titrated insulin glargine added orforglipron or placebo. Orforglipron decreased A1C by 1.5%-2.1% after 40 weeks compared with 0.8% on placebo. These reductions were statistically significant, and the drug also led to weight loss in combination with basal insulin.

An article in Endocrine News summarised these findings, noting that the pill achieved superior glycemic control over both SGLT 2 therapy and placebo. The safety profile remained consistent with other GLP-1 drugs, with mild-to-moderate gastrointestinal events being the most common, and no liver safety issues were seen.

Summary of orforglipron’s weight loss efficacy

Trial

 Population Dose (mg/day) Mean % weight loss

Placebo
ATTAIN 1

Adults with obesity (no diabetes)

6

7.8%

0.9%

12

9.3%

36

12.4%
ATTAIN 2

Adults with obesity + type 2 diabetes

6

5.1%

2.5%

12

7.0%

36

9.6%
ATTAIN MAINTAIN

Prior users of semaglutide or tirzepatide

Maintained weight loss (0.9 kg and 5 kg regain) vs >9 kg weight regain on placebo

Comparing orforglipron to other weight loss medications

Here’s how orforglipron compares with other weight loss medications in terms of effectiveness.

Orforglipron vs. semaglutide (Wegovy and Wegovy pill)

Semaglutide is available as a weekly injection (Wegovy) and a daily tablet (Wegovy pill). In trials, Wegovy injection achieved around 15% average weight loss over 68 weeks, while the Wegovy pill delivered a 13.6% reduction after 64 weeks.

Orforglipron’s highest dose produced 12.4% weight loss at 72 weeks. Thus, semaglutide injections still lead to slightly greater weight reduction, but orforglipron comes close while offering the convenience of a pill. Unlike the Wegovy pill, orforglipron can be taken without fasting.

Orforglipron vs. tirzepatide (Zepbound)

Tirzepatide is a dual GLP-1/GIP receptor agonist that is injected weekly. Clinical trials (SURMOUNT 1 and 2) have shown 15%-21% weight loss at 72 weeks, substantially more than orforglipron’s 12.4% average. Tirzepatide’s dual mechanism may explain its greater effect on weight.

Orforglipron may appeal to people who dislike needles or who need a flexible dosing schedule. Its efficacy approaches that of semaglutide and is well ahead of older injectable GLP-1 drugs such as liraglutide (Saxenda).

Potential benefits of orforglipron beyond weight loss

Beyond reducing body weight, orforglipron has shown improvements in multiple metabolic parameters. In ATTAIN 1 and ATTAIN 2, participants on orforglipron experienced reductions in waist circumference, blood pressure, triglycerides, and non-HDL cholesterol. High-sensitivity C-reactive protein, an inflammation marker associated with cardiovascular risk, decreased by nearly 48% at the 36 mg dose.

In type 2 diabetes trials, the drug lowered A1C by up to 2.1% when combined with insulin glargine. These cardiometabolic benefits may reduce long-term complications of obesity and diabetes.

An additional benefit is convenience. Taking a small pill once daily without restrictions could improve adherence and quality of life compared with weekly injections or tablets that require strict fasting. This could be particularly helpful for people with busy schedules or needle phobias.

Safety and potential side effects of orforglipron

Across clinical trials, the most frequently reported side effects of orforglipron were gastrointestinal. Participants experienced:

    • nausea
    • vomiting
    • diarrhea
    • constipation
    • indigestion
    • burping

These symptoms were usually mild to moderate, occurred mostly during the initial dose escalation, and tended to improve over time. Headache, fatigue, dizziness, and acid reflux appeared less often.

As with other GLP-1 agonists, rare serious events such as pancreatitis, gallbladder inflammation, or acute cholecystitis have been reported. The numbers are small, and the relationship remains uncertain since rapid weight loss itself can increase the risk of gallstones and pancreatitis.

If approved, orforglipron’s label will likely carry warnings about thyroid tumors, as seen with other GLP-1 drugs, and contraindications for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. The drug has not been studied extensively in pregnant or breastfeeding individuals, and its safety in those populations remains unknown.

Discontinuation rates

In ATTAIN 1, discontinuation due to adverse events was 5.1% for the 6 mg dose, 7.7% for 12 mg, and 10.3% for 36 mg, compared with 2.6% for placebo. Total discontinuation rates (for any reason) were slightly lower with orforglipron than placebo, which may reflect better perceived benefits.

No hepatic (liver) safety signals were observed in the phase 3 trials.

When will orforglipron be available?

Orforglipron availability in the US

Lilly submitted orforglipron to the FDA for obesity treatment in 2025 and plans to file for a type 2 diabetes indication in 2026. The company originally expected approval by March 2026, but the review timeline was extended to April 10, 2026, under the Commissioner’s National Priority Review Voucher pilot program.

If approved, orforglipron could become available in mid-2026.

How much will orforglipron cost?

Pricing will depend on insurance coverage and government agreements. Lilly’s agreement with the US government indicates that Medicare beneficiaries would pay no more than $50 per month for orforglipron (and Zepbound) starting in April 2026.

Self-pay patients could access orforglipron through the LillyDirect pharmacy channel with prices starting at $149 for the lowest dose and up to $399 for higher doses. The company has not yet disclosed the official list price, so costs may vary.

Who might benefit from orforglipron?

Clinical trials enrolled adults with obesity (body mass index of 30 kg/m² or more) or overweight (BMI 27 kg/m² or more) who had at least one weight-related comorbidity. Participants with type 2 diabetes were included in the ATTAIN 2 and ACHIEVE trials.

Orforglipron may be a good option for individuals who:

    • Prefer an oral pill over injections
    • Need flexible dosing without fasting or water restrictions
    • Have obesity or overweight with or without type 2 diabetes, and are looking for significant but not extreme weight loss
    • Want to maintain weight loss achieved through injectable therapies

However, orforglipron may not be appropriate for people with a history of medullary thyroid carcinoma or MEN2, those who are pregnant or breastfeeding, or individuals with uncontrolled gastrointestinal disorders.

Your healthcare provider will evaluate your medical history, medications, and weight loss goals before prescribing orforglipron.

Bottom line

Orforglipron is an investigational once-daily oral GLP-1 that has shown up to 12.4% weight loss and up to 2.1% A1C reduction in phase 3 trials. It offers a needle-free option with flexible dosing and has demonstrated the ability to help maintain weight loss after injectable therapy. Side effects are mostly gastrointestinal and similar to those of other GLP-1 drugs.

FDA review is ongoing, with a decision expected in 2026. If approved, orforglipron could expand access to effective weight management through a convenient oral option at projected lower self-pay and Medicare costs.

Related Articles

Frequently Asked Questions

The US Food and Drug Administration is reviewing orforglipron for weight loss therapy under the National Priority Voucher program. Lilly originally expected approval by March 2026, but the agency extended its decision deadline to April 10, 2026. If approved on that date, the pill could reach pharmacies by mid-2026. As of this writing (February 2026), orforglipron remains investigational and cannot be prescribed.

Clinical trials have reported mostly gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation, indigestion, and burping were the most common and were typically mild to moderate. Headache, fatigue, and dizziness occurred less often. Rare but serious events like pancreatitis or gallbladder inflammation have been documented, though the incidence appears low. Long-term safety data are still emerging.

No. Orforglipron is a once-daily oral pill that activates only the GLP-1 receptor, while tirzepatide (brand names Zepbound and Mounjaro) is a weekly injection that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Tirzepatide generally produces greater weight loss (15%-22%) but can only be administered by injection.

In clinical trials, participants began losing weight within weeks of starting orforglipron, but the most notable changes occurred over several months. ATTAIN 1 showed that weight loss continued through the 72-week study period, with about half of the total loss occurring by week 36. For blood sugar control, A1C reductions were evident at 40 weeks in ACHIEVE 2 and ACHIEVE 5. Individual responses will vary, and your healthcare provider will guide dose adjustments over time.

Zepbound is the brand name for tirzepatide, a dual GIP/GLP-1 receptor agonist delivered by weekly injection. It is FDA-approved for chronic weight management and type 2 diabetes. Orforglipron is a small-molecule GLP-1 receptor agonist taken as a daily pill. Trial data suggest orforglipron yields about 12% weight loss, whereas tirzepatide can reach 15%-22%. Orforglipron does not yet have an official dose or approval but is under FDA review.

Pricing has not been finalized. Lilly’s agreement with the US government states that Medicare beneficiaries will pay no more than $50 per month for orforglipron if it is approved. For self-pay patients, Lilly plans to offer the pill through its LillyDirect pharmacy channel starting at $149 for the lowest dose, with higher doses up to $399. Final list prices will be announced once regulatory approval is granted.

Adults with obesity or overweight with at least one weight-related health issue may be considered for orforglipron. The drug is being studied both for people without diabetes and those with type 2 diabetes. It may also suit individuals who want to maintain weight loss after stopping injectable GLP-1 therapies. A healthcare professional can determine eligibility based on medical history and treatment goals.

Orforglipron offers several potential benefits. It delivers significant weight loss (around 12.4% at the highest dose) and improves cardiometabolic health by reducing blood sugar, blood pressure, triglycerides, and inflammatory markers. The once-daily pill requires no injections or fasting, which could improve adherence and quality of life. Early evidence also suggests it helps maintain weight loss achieved with injectable medications.

Sources

Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R. (2025). Orforglipron, an oral Small-Molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. https://doi.org/10.1056/nejmoa2511774

Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., Wu, Q., Stefanski, A., & Jouravskaya, I. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet, 406(10522), 2927–2944. https://doi.org/10.1016/s0140-6736(25)02165-8

Giara, K. (2026, February 11). Orforglipron and its unique delivery method could expand obesity treatment options. MedCentral. https://www.medcentral.com/obesity/orforglipron-oral-obesity-glp-1-unique-delivery-fda-decision

Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after

Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight

Wharton, S., Lingvay, I., Bogdanski, P., Vale, R. D. D., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/nejmoa2500969

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183

Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-superior-glycemic

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038

Oberst, J. (2026, February 11). Lilly’s oral GLP-1 orforglipron demonstrates superiority in phase 3 diabetes trials. Endocrine News. https://endocrinenews.endocrine.org/lillys-oral-glp-1-orforglipron-demonstrates-superiority-in-phase-3-diabetes-trials/

Lilly’s oral GLP-1 data “as good as it gets” at 12% weight loss, exec says. (2025, August 7). Fierce Biotech. https://www.fiercebiotech.com/biotech/lilly-preps-oral-glp-1-regulatory-review-after-phase-3-shows-12-weight-loss

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines

What to know about Orforglipron oral GLP-1 | Eli Lilly and Company. (n.d.). https://www.lilly.com/news/stories/what-to-know-about-orforglipron

Manalac, T. (2026, January 16). FDA delays decision for Lilly’s obesity pill Orforglipron, Other priority voucher awardees: report. BioSpace. https://www.biospace.com/fda/fda-delays-decision-for-lillys-obesity-pill-orforglipron-other-priority-voucher-awardees-report